<DOC>
	<DOCNO>NCT00403845</DOCNO>
	<brief_summary>The study design obtain data efficacy safety 3 dos indacaterol ( 150 , 300 , 600 µg ) Japanese patient chronic obstructive pulmonary disease ( COPD ) optimal dose ( ) could choose test late study .</brief_summary>
	<brief_title>Dose Ranging Study Indacaterol Japanese Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female Japanese age 40 75 year old Moderate severe chronic obstructive pulmonary disease ( COPD ) smoke history least 20 pack year History hospitalization COPD exacerbation within past 6 month Use longterm oxygen therapy History asthma Respiratory tract infection within past 1 month Consistently high low blood sugar Clinically abnormal laboratory value significant condition History heart failure heart attack within past 6 month History long QT syndrome long QT interval electrocardiogram record screen Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>QAB149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long act β2-agonist</keyword>
</DOC>